Artificial Tumor Kits® in ready-to-use microplates for in vitro testing.

Artificial tumors® (3D cultures) from tumor cell lines widely used in oncology, and in particular derived from aggressive triple-negative breast cancers.

• Artificial tumors more closely mimic the microenvironment of avascular tumors in vivo than 2D cultures
• These models are increasingly becoming part of the drug development processes.

Discover

Complete, ready-to-use serum-free cell culture media.

OptiPASS® media used for monolayer (2D) culture of tumour or healthy cells and for 3D culture of a wide range of tumour types of pre-clinical/clinical interest.

Three applications:

Bioproduction-2D culture

For the 2D culture of VERO E6 cells, the OptiPASS® medium (OPTI04) allows:

• Cell proliferation and viability similar to serum medium culture (reference
• Preservation of cell phenotype

(Requires prior coating of culture plates)

Oncology- 3D culture

Examples of 3D cultures with OptiPASS® medium: tumour lines validated in 2D and 3D cultures:

• Breast: MDA-MB-231, SUM1315, BT474
• Prostate: PC-3
• Lung : NCI-H1975
• Ovary: SK-OV-3

For artificial tumour cultures®, the OptiPASS® medium (OPTI03) allows:

• Maintaining / increasing the rate of proliferation / growth
• Maintenance of metabolic gradients within cultures (live cells/dead cells)
• Reproducibility of production in terms of size and proliferation/growth

Oncology-preservation

Once produced, the 3D cultures can be stored for several days in OptiPASS® (OPTI05), under anoxic conditions and at 4°C before being analysed. Examples of tumour lines validated with this method: breast: MDA-MB-231, SUM1315.

Discover

Innovation improving the detection, localisation and quantification of MultiDrug Resistance proteins in all cellular samples.
Applications:

• Better control of efflux: kidney, liver, blood-brain barrier, placental barrier, etc
• Evaluate cellular resistance to different molecules and exogenous agents (active ingredients, pollutants, anti-infectious agents)

Aims:

• Optimising cancer treatment by quantifying chemoresistance of certain drugs
• Improving efflux modulation

Available for different excitation/emission wavelengths.

Development of new 3D tumour cell models on demand.

• Analysis of requirements according to the cell type and choice of the most suitable 3D technique
• Identification of optimal growing conditions:
  • Choice of culture device (specific microplates)
  • Cell concentrations, type and matrix concentration (if applicable)
  • Objective: reproducibility and stability of models (coefficient of variation in size <10%)
• Characterisation of models:
  • Growth profile
  • Metabolic profile
  • Maximum cultivation time
  • Topology (Scanning Electron Microscopy SEM)
  • Ultrastructure (Transmission Electron Microscopy TEM)
  • Expression profile of proteins of interest
• Deliverables:
  • 3D cell culture protocol adapted to your cell type
  • Ready-to-use kits containing your 3D models (if development possible in OptiPASS®)
• Estimated development time: between 2 and 3 months depending on the models

Development of new 3D tumour cell models on demand.

• Requirement analysis
• Choice of tumour models
• Development of adapted tests (when appropriate)
• Identification of treatment modalities / duration / type of exposure / doses
• Reception and preparation of test molecules
• Carrying out the tests
• Identification of deliverables (non-exhaustive)
  • Viability %, Growth inhibition, IC50,
  • Impact on the cell cycle
  • Tagging and quantification of targets of interest
  • Clonogenic tests, etc.
• Secure archiving of raw and analysed data
• Deliverables: full analysis reports
• Deliverables: full analysis reports